Novartis, Amgen, Ionis shares slide after pelacarsen trial fail
Novartis, Amgen and Ionis shares are lower after Novartis’ pelacarsen failed to reduce heart risks, despite lowering harmful cholesterol Lp(a).
Story updates
09:54:00 AM UTC
SquawkNews
By George GloverBig Pharma has been scrambling to restock its pipelines this year-so a disappointing trial from one drugmaker can have an outsize knock-on impact for rivals trying to develop similar treatments.That dynamic was playing out on Tuesday, as a major setback for Switzerland's Novartis sp…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.